Supplemental Digital Content
|
|
|
- Anne Harmon
- 6 years ago
- Views:
Transcription
1 PharmacoEconomics Do Productivity Costs Matter? The Impact of Including Productivity Costs on the Cost Effectiveness of Interventions Targeted at Depressive Disorders Krol M, et al. Supplemental Digital Content This Supplemental Digital Content contains the information referred to in the full version of this article, which can be found at Adis Data Information BV. All rights reserved
2 Appendix Economic evaluations including productivity costs Study Comparators (comparisons) Months Effect PC methodology (data collection, PC PC per TC per % PC IC -PC (b) IC +PC (b) IC change (b) follow-up measure data collected, values attached) approach month (b) month (b) of TC Bosmans et.al. UCnoAD 12 (i) MADRS Cost diaries. Absenteeism. Mean FCA % (2008) The UCAD (ii) QALYs age sex-specific income. Unpaid % Netherlands (61) (UCAD vs. UCnoAD) (a) work with shadow price method (d) Stant et.al. (2008) The Netherlands (63) Sørensen et.al. (2007) Denmark (45) Bosmans et.al. (2007) The Netherlands (60) Sobocki et.al. (2006) Sweden (58) Kendrick et.al. (2006) United Kingdom (68) Smit et.al. (2006) The Netherlands (62) TAU 18 SCL-90 Questionnaires. Absenteeism, FCA % CST Dutch standard prices not further % (CST vs. TAU) (a) specified - 1, Citalopram 6 Success rate Survey among medical doctors. HCA 853 1,208 71% Escitalopram (MADRS) Absenteeism. Sick fund payments 750 1,084 69% (Escitalopram vs. Citalopram) (a) Venlafaxine-XR % Escitalopram % (Escitalopram vs. Venlafaxine-XR) (a) UC 6 SCL-90 Questionnaires. Absenteeism. FCA % Pharmacist coaching Average age+sex-dependent % (Pharmacists coaching vs. UC) (a) income UC 60 QALYs Literature. Absenteeism HCA NS NS - Hypothetical AD therapy NS NS - (Hypothetical AD therapy vs. UC) (a) , Usual GP care 6 QALYs Questionnaires. Absenteeism. HCA 1,024 1,109 92% Generic nurse care Average national gender 999 1,161 86% (Generic nurse care vs. Usual GP dependent earnings care) (a) PST 1,590 1,761 90% (PST vs. Usual GP care) (a) 511 3,907 3,396 UC 12 IRDD Questionnaire: TIC-P. FCA % CBT Absenteeism, presenteeism and % (CBT vs. UC) (a) unpaid work. Average age and sexdependent - 5-1,954-1,948 earnings. Unpaid work by shadow price
3 Serrano-Blanco et.al. (2006) Spain (55) van Baardewijk et.al. (2005) The Netherlands (64) Wade et.al. (2005) United Kingdom (70) Wade et.al. (2005) United Kingdom (71) Demyttenaere et.al. (2005) Belgium (39) Fernandez et.al. (2005) United Kingdom (67) François et.al. (2003) Norway (54) FLU 0 (i) MADRS Questionnaires. Authorized HCA 63% IMI (ii) CGI absenteeism. Minimum wage 59% (IMI vs. FLU) (a) FLU % IMI % (IMI vs. FLU) (a) FLU % IMI % (IMI vs. FLU) (a) (d) FLU % IMI % (IMI vs. FLU) (a) Venlafaxine-XR 6 (i) Success Absenteeism. Average national HCA 1,412 2,100 67% Duloxine rate (HAM-D hourly wages 1,460 2,204 66% (Duloxine vs. Venlafaxine-XR) (a) or MADRS) (ii) SFDs Citalopram 6 Success rate Absenteeism. Average market HCA % Escitalopram (MADRS) wages % Escitalopram vs. Citalopram (a) Citalopram 6 Success rate Absenteeism. Average market HCA % Escitalopram (MADRS) wages % (Escitalopram vs. Citalopram) (a) Venlafaxine-XR % Escitalopram % (Escitalopram vs. Venlafaxine-XR) (a) Citalopram 6 Success rate Literature. Absenteeism FCA % Escitalopram (MADRS) % (Escitalopram vs. Citalopram) (a) Venlafaxine-XR % Escitalopram % (Escitalopram vs. Venlafaxine-XR) (a) Venlafaxine-XR 2 QALYs Questionnaires. Absenteeism. HCA % Escitalopram Average national wage based daily % (Escitalopram vs. Venlafaxine-XR) (a) benefits paid by sickness insurance for period off work. Citalopram 6 Success rate Literature. Absenteeism. Norway HCA % Fluoxetine (MADRS) statistics % Venlafaxine-XR %
4 Citalopram 6 Success rate Citalopram Success rate Escitalopram % (Escitalopram vs. Citalopram) (a) (Escitalopram vs. Fluoxetine) (a) (Escitalopram vs. Venlafaxine-XR) (a) McCrone et.al. TAU 6 (i) QALYs Absenteeism with doctors HCA % (2004) United BtB (ii) BDI certificate. Age+gender dependent % Kingdom (73) (BtB vs. TAU) (a) national average daily wages TAU % BtB % (BtB vs. TAU) (a) (d) Hemels et.al. Absenteeism. Market wage rates. HCA % (2004) Austria (37) Escitalopram (MADRS) % (Escitalopram vs. Citalopram) (a) Hemels et.al. Absenteeism. Market wage rates. HCA % (2004) Austria (38) Escitalopram (MADRS) % (Escitalopram vs. Citalopram) (a) Romeo et.al. Paroxetine 5.5 (i) Success Questionnaires. Absenteeism. HCA % (2004) United Mirtazapine rate(17- National average wage rates % Kingdom (69) (Mirtazapine vs. Paroxetine) (a) HAMD) (ii) Change in QLDS Browne et.al. IPT 12 MADRS Questionnaires. Absenteeism. HCA % (2002) Canada SSRI Unemployment insurance % (41) SSRI + IPT payments % (SSRI vs. IPT) (a) (SSRI + IPT vs. IPT) (a) - 1,184-1, (SSRI + IPT vs. SSRI) (a) - 1,671-1, IPT % SSRI % SSRI + IPT % (SSRI vs. IPT) (a) 1,695 1, (SSRI + IPT vs. IPT) (a) 1,251 1, (SSRI + IPT vs. SSRI) (a) Nuijten et.al. Discontinuation of TCA for 9 months 9 (i) TWD Literature. Absenteeism. Value of FCA % (2001) The Netherlands (59) + termination Discontinuation of TCA for 9 months + prolongation (ii) QALYs days lost based on GDP per capita % (Discontinuation of TCA for 9 months + prolongation vs. discontinuation of TCA for 9 months
5 Valenstein et.al. (2001) United States of America (90) + termination) (a) % termination % prolongation ( prolongation vs. Continuation of TCA for 9 months + termination) (a) Discontinuation of TCA for 9 months % + termination Discontinuation of TCA for % months + prolongation (Discontinuation of TCA for 9 months + prolongation vs. discontinuation of TCA for 9 months + termination) (a) % termination % prolongation (Continuation of TCA for a 9 months + prolongation vs. Continuation of TCA for 9 months + termination) (a) No screening followed by UC Lifetime QALYs Literature. Absenteeism and HCA NS NS - Annual screening presenteeism. NS NS - (Annual screening vs. no screening followed by UC) (a) Periodic screening every 3 years NS NS - (Periodic screening every 3 years vs. no screening followed by UC) (a) Periodic screening every 5 years NS NS - (Periodic screening every 5 years vs. no screening followed by UC) (a) One-time screening NS NS - (One-time screening vs. no screening followed by UC) (a) Opportunistic screening NS NS - (Opportunistic screening vs. no screening followed by UC) (a) King et.al. (2000) Routine GP care 4 (i) BDI Questionnaires. Absenteeism. HCA % , , ,959 (c) 245,987 (c) 36,028 89,120 (c) 126,481 (c) 37,361 55,629 (c) 93,477 (c) 37,848 34,970 (c) 49,421 (c) 14, ,205 (c) 327,184 (c) - 12,022
6 United Kingdom (72) CBT (ii) QALYs Patients gross income % NDC % (CBT vs. GP care) (a) (NDC vs. GP care) (a) Routine GP care % CBT % NDC % (CBT vs. GP care) (a) (NDC vs. GP care) (a) Literature. Absenteeism. Sick fund HCA 886 1,320 67% Brown et.al. (1999) Austria (36) Amitriptyline Mirtazapine 6.5 Success rate (17-HAMD) payments ,292 65% (Mirtazapine vs. Amitriptyline) (a) (d) Fluoxetine ,320 66% Mirtazapine ,327 65% (Mirtazapine vs. Fluoxetine) (a) TCAs 18 TWD Literature. Absenteeism. Value of Nuijten et.al. HCA % (1998) France (48) Fluvoxamine days lost based on GDP per capita % (Fluvoxamine vs. TCAs) (a) ,342-1,932 Antonuccio et.al. Fluoxetine 24 Treatment Literature. Absenteeism. Average HCA 912 1,644 55% (2004) United Combination of both protocols success, NS net wage rate ,671 49% States (91) Individual CBT 812 1,267 64% Group CBT 812 1,237 66% (Individual CBT vs. Fluoxetine) (a) - 6,626-9,033-2,407 (Group CBT vs. Fluoxetine) (a) - 7,366-9,772-2,407 (Individual CBT vs. Combination - 9,449-9, both protocols) (a) (Group CBT vs. Combination both protocols) (a) - 10,188-10, Löthgren et.al. (2004) Sweden (57) Borghi et.al. (2000) United Kingdom (66) Citalopram 6 Success rate Literature. Absenteeism. Average HCA % Escitalopram (MADRS) national wage rates % (Escitalopram vs. Citalopram) (a) Venlafaxine-XR % Escitalopram % (Escitalopram vs. Venlafaxine-XR) (a) Amitriptyline 6.5 Success rate Literature. Absenteeism. Value of HCA % Mirtazapine (17-HAMD) days lost based on GDP per capita % (Mirtazapine vs. Amitriptyline) (a) Fluoxetine % Mirtazapine % (Mirtazapine vs. Fluoxetine) (a)
7 Amitriptyline 6.5 Success rate Brown et.al. Retrospective interviews with HCA 3,036 3,728 81% (1999) Austria (47) Mirtazapine (17-HAMD) medical doctors. Absenteeism. 2,892 3,560 81% (Mirtazapine vs. Amitriptyline) (a) Sick fund payments. Value of days lost based on GDP per capita , Fluoxetine 6 Success rate Brown et.al. Retrospective interviews with HCA 3,224 3,960 81% (2000) Austria (46) Mirtazapine (17-HAMD) medical doctors. Absenteeism. 3,210 3,950 81% (Mirtazapine vs. Fluoxetine) (a) Value of days lost based on GDP per capita (d) Zhang et.al. GP 12 NS Questionnaires baseline. HCA NS NS - (1999) United MHS Absenteeism. Patients wages. NS NS - States (92) (MHS vs. GP) (a) 1, ,387 (d) (a) New intervention versus comparator (b) in Euros 2007 per patient (c) Costs per QALY gained (d) shift in cost-saving/costing PC = productivity costs TC = Total costs (direct costs + PC) IC = Incremental cost FCA = Friction cost approach HCA = Human capital approach Vs. = versus NS = not specified UC = Usual care AD = Antidepressant UCnoAD = Usual care without antidepressants UCAD = Usual care with antidepressants TAU = Treatment as usual CST = Cognitive Self-Therapy XR = extended-release GP = General Practioner PST = Nurse problem-solving treatment FLU = Fluoxetine IMI = Imipramine BtB = Beating the Blues, computerized therapy program of a 15 min introductory video followed by 8 50 min sessions of cognitive-behavioral therapy IPT = Interpersonal Psychotherapy SSRI = Sertraline, a selective serotonin reuptake inhibiting TCA = Tricyclic antidepressant CBT = Cognitive-behavior therapy NDC = Nondirective counseling MHS = Mental Health Specialist MADRS = Montgomery Asberg Depression Rating Scale QALY = Quality Adjusted Life Year SCL-90 = Hopkins Symptom Checklist 90 IRDD = Incidence rate of depressive disorder HAM-D = Hamilton Rating Scale for Depression SFD = symptom-free days CGI = Checklist Clinical Global Impression BDI = Beck Depression Inventory QLDS = Quality of Life in Depression Scale TWD = Time without depression
Appendix 15. Evidence Tables for Economic Studies
year and Borghi & Guest, UK. 2000 Comparators: Mirtazapine Amitriptyline Fluoxetine Study population Study design data source Patients in the UK, with moderate and severe depression, and within the age
Setting The setting was primary and secondary care. The economic study was carried out in the UK.
A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom Wade A G, Toumi I, Hemels M E H Record Status This is a critical abstract of
Setting The setting was primary care. The economic study was carried out in the UK.
A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK Wade A G, Toumi I, Hemels M E Record Status
Treating Depression in Disadvantaged Women: What is the evidence?
Treating Depression in Disadvantaged Women: What is the evidence? Megan Dwight Johnson, MD MPH Associate Professor Medical Director, UWMC Inpatient Psychiatry Department of Psychiatry and Behavioral Sciences
Depression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
Major Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
Study population Patients in the UK, with moderate and severe depression, and within the age range 18 to 93 years.
Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Borghi J, Guest J F Record Status This is a critical abstract
Studie 083 (950E-CNS )
Studie 083 (950E-CNS-0005-083) Studienberichtssynopse Clinical Study Report 950E-CNS-0005-083 EFFECTS OF THE USE OF REBOXETINE AS A SUBSTITUTE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS
Depression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, 593 600 described, 594 596 DSM-V changes related to,
Appendix 15. Evidence Tables for Economic Studies
Kaltenhaler, 2002. UK Comparators: Computerised Cognitive Behaviour therapy (CCBT) Beating the Blues (BtB): nine sessions: a 15-minute introductory video followed by eight 1- hour therapy sessions. CCBT
Volume 4; Number 5 May 2010
Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated
Supplementary figures and tables. Figure A: Study schematic
Supplementary figures and tables Figure A: Study schematic Figure B: Percent of patients with a normal (green), borderline (beige), abnormal (brown), or high (red) electrocardiogram 14-90 days after prescription
MENTAL HEALTH DISORDERS: THE ECONOMIC CASE FOR ACTION Mark Pearson Head of Department, OECD Health Division
MENTAL HEALTH DISORDERS: THE ECONOMIC CASE FOR ACTION Mark Pearson Head of Department, OECD Health Division The costs of poor mental health Estimates of Direct and Indirect Costs of Mental Illness 1 All
Costs: description and values Outcomes: description and values. Costs: Consultations with psychologists, psychiatrists, GPs
Appendix 16f: Evidence tables for economic studies High intensity psychological interventions for Generalised Anxiety Disorder Reference to included study Heuzenroeder L, Donnelly M, Haby MM, Mihalopoulos
Assessment of Clinical Guidelines for Continuation Treatment in Major Depression
Volume 4 Number 4 2001 VALUE IN HEALTH Assessment of Clinical Guidelines for Continuation Treatment in Major Depression Mark J. C. Nuijten, MD, MBA MEDTAP International, Amsterdam, The Netherlands ABSTRACT
KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
Treating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
This initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
Clinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
Major Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
Comparison of Different Antidepressants and Psychotherapy in the Short-term Treatment of Depression
ORIGINAL COMPARISON PAPER OF DIFFERENT ANTIDEPRESSANTS AND PSYCHOTHERAPY IN THE SHORT-TERM TREATMENT OF DEPRESSION Comparison of Different Antidepressants and Psychotherapy in the Short-term Treatment
Pharmacotherapy of depression
Pharmacotherapy of depression Stuff you already know Stuff you probably know Stuff you possibly don t know Stuff you thought you knew but are mistaken about How long does it take for antidepressants
SUPPLEMENTARY INFORMATION
Supplementary Table 2. Worldwide studies of SLE costs Authors Country Study period (year(s) expenses were incurred) Chiu et al. 17 Cho et al. 172 Zhu et al. 174 Zhu et al. 173 Sutcliffe et al. 171 Doria
Treatment Quad Cities Eating Disorders Consortium
Treatment Quad Cities Eating Disorders Consortium James E. Mitchell, MD UND School of Medicine and Health Sciences Neuropsychiatric Research Institute ANOREXIA NERVOSA BULIMIA NERVOSA BINGE EATING DISORDER
CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
The legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
#CHAIR2016. September 16 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 16 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Depression in Children and Adolescents Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, TX Karen Dineen
Index. Bulimia, 13 Bupropion, 12, 51 Buspirone, 81
Index A α-adrenergic blockade, 55 Ablative neurosurgery, 83 Activity scheduling, 61 Acupuncture, 64, 69 71 Alcohol, 7, 13 Alprazolam, 50 Amfebutamone, 52 Amitriptyline, 34 Anhedonia, 13, 17, 18 Anterior
Depression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
Mood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium
PharmacoEconomics (2014) 32:479 493 DOI 10.1007/s40273-014-0138-x ORIGINAL RESEARCH ARTICLE Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive
Antidepressant tapering advice
Antidepressant tapering advice Professor Tony Kendrick et al, NIHR REDUCE Programme in the UK has kindly made this available to New Zealand prescribers as there is little empirical evidence on how to taper
Drug Class Review on Second Generation Antidepressants
Drug Class Review on Second Generation Antidepressants Final Report Update 1 July 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles
Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
Dr.Rahiminejad Roozbeh Hospital TUMS
Dr.Rahiminejad Roozbeh Hospital TUMS Psychiatric disorders, particularly depression, anxiety and eating disorders, are prevalent in diabetes. Mental illness increases risk of diabetes and diabetic complications.
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014)
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014) Date of Preparation: September 2014 Date for next full
A Healthy Outlook. Recognizing the Signs & Getting Help for Late-life Depression Patricia A. Arean, PhD Professor UCSF
A Healthy Outlook Recognizing the Signs & Getting Help for Late-life Depression Patricia A. Arean, PhD Professor UCSF What We ll Talk About Today Depression in older adults: some facts and some myths Why
TRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 12 June 2013 SEROPLEX 5 mg, film-coated tablet B/14 (CIP: 3400936428973) B/28 (CIP: 3400935993519) SEROPLEX 10 mg,
Efficacy and Acceptability of Pharmacological Treatments for Post- Stroke Depression: A Bayesian Network Meta-Analysis
Efficacy and Acceptability of Pharmacological Treatments for Post- Stroke Depression: A Bayesian Network Meta-Analysis Presenter: Miss Deng Tutor: Prof. Liu Ming Department of Neurology West China Hospital
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update 1 Guideline title Anxiety: management of generalised anxiety disorder in adults in primary, secondary and community care (update)
MORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)
Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories
Setting The setting was primary and secondary care. The economic evaluation was conducted in France.
Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an
Antidepressants. BMF 83 - Antidepressants
Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals in the brain, namely serotonin and
It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
Effective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta367
Vortioxetine for treating major depressive e episodes Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta367 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
Antidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
Drug Class Review Second Generation Antidepressants
Drug Class Review Second Generation Antidepressants October 2008 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs
Diabetes and Depression. Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C
Diabetes and Depression Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C 2008 Learning Objectives State the risk factors for depression Identify the vulnerability
Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR
Pre - PA Allowance 12 years of age or older Quantity Immediate-release Formulation Ultracet 720 dosage units per 90 days OR Ultram 720 dosage units per 90 days Extended-release Formulations Ultram ER 90
Can self-reported depression be helped by homeopaths?
Can self-reported depression be helped by homeopaths? A pragmatic cohort randomised controlled trial with qualitative interviews with patients. Tables, figures and appendixes Petter Viksveen Tables, figures
Reviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options
Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
Rating Scales. Chris Smart
Rating Scales Chris Smart Overview General Points Purpose Diagnosis-specific: Depression, Mania, Anxiety, OCD, Schizophrenia, Dependence, Eating Disorder, Personality Disorder Pan-diagnoses/ Functional
ers_practice_parameter.pdf
These Guidelines were based in part from on following: Treatment of Patients With Major Depressive Disorder from the American Psychiatric Association (APA) that was amended by the following Guideline Watch
Supplementary Online Content
Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published
Indirect costs of inflammatory bowel diseases: Crohn s disease and ulcerative colitis. A systematic review
Systematic review/meta-analysis Indirect costs of inflammatory bowel diseases: Crohn s disease and ulcerative colitis. A systematic review Paweł Kawalec Drug Management Department, Institute of Public
Depression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
Anxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
Program
Mental health@work Video conference Program Mentalhealth@work Introduction (David Rebergen, chair) Health management/work Disability Prevention 11.05-11.20: Assessment by virtual role play E. Pouw 11.20-11.35:
MEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)
Protocol Title: Depression & Generalized Anxiety Disorder Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017) Group
Clinical Pharmacogenomics in Depression Treatment
Clinical Pharmacogenomics in Depression Treatment GORDON ANG, PHARMD PGY- 2 PSYCHIATRIC PHARMACY RESIDENT CENTRAL TEXAS VETERANS HEALTH CARE SYSTEM 1 Abbreviations CGI-S: Clinical Global Impression Severity
1 High intensity psychological interventions for generalised anxiety disorder
1 High intensity psychological interventions for generalised anxiety disorder Reference to included study Heuzenroeder L, Donnelly M, Haby MM, Mihalopoulos C, Rossell R, Carter R, Andrews G, Vos T (2004)
Children s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
DATE: 11 June 2015 CONTEXT AND POLICY ISSUES
TITLE: Second Generation Antidepressants for Pediatric patients with Major Depressive Disorder and Anxiety Disorder: A Review of the Clinical Effectiveness and Safety DATE: 11 June 2015 CONTEXT AND POLICY
A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response*
Arch Womens Ment Health (2003) 6: 147 151 DOI 10.1007/s00737-003-0172-8 Short communication A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response* T.
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
CNS Drugs (2012) 26:1033 1049 DOI 10.1007/s40263-012-0010-5 REVIEW ARTICLE Rediscovering for the Treatment of Major Depressive Disorder Andrea Fagiolini Alessandro Comandini Mario Catena Dell Osso Siegfried
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
Duragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist
Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have
Post-traumatic stress disorder
National Institute for Health and Care Excellence Final Post-traumatic stress disorder [F] Evidence reviews for pharmacological interventions for the prevention and treatment of PTSD in adults NICE guideline
The health economic landscape of cancer in Europe
1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor
Reviews/Evaluations. Guidelines for Cost-Effective Use of Antidepressants. Current Utilization (January 1, 2002 through December 31, 2002)
Reviews/Evaluations Guidelines for Cost-Effective Use of Antidepressants Current Utilization (January 1, 2002 through December 31, 2002) OHP spent $54 million on antidepressant medications (Class 11) Drug
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.
Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.1 December 2018) Date of Preparation: January 2018 (with addition of
The Detection and Treatment of Perinatal Depression in Medical Settings
The Detection and Treatment of Perinatal Depression in Medical Settings Ryan J Van Lieshout, MD, PhD, FRCP(C) Albert Einstein/Irving Zucker Chair in Neuroscience Assistant Professor, Department of Psychiatry
NHFA CONSENSUS STATEMENT ON DEPRESSION IN PATIENTS WITH CORONARY HEART DISEASE
NHFA CONSENSUS STATEMENT ON DEPRESSION IN PATIENTS WITH CORONARY HEART DISEASE Associate Professor David Colquhoun 19th October 2013 University of Queensland, Wesley & Greenslopes Hospitals, Brisbane,
Annex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for granisetron
Technology appraisal guidance Published: 22 February 2006 nice.org.uk/guidance/ta97
Computerised cognitive behaviour therapy for depression and anxiety Technology appraisal guidance Published: 22 February 2006 nice.org.uk/guidance/ta97 NICE 2017. All rights reserved. Subject to Notice
Are Anti depressants Effective in the Treatment of Depressed Patients Who Do Not Seek Psychotherapy?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Are Anti depressants Effective in the
Efficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence
Efficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence J. Craig Nelson, M.D., Kevin Delucchi, Ph.D., Lon S. Schneider, M.D. Objective: Second-generation
Treatment of Anxiety (without benzos)
Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common
Reviewing the long-term use of selective serotonin reuptake inhibitors in patients with depression
CLINICAL AUDIT Reviewing the long-term use of selective serotonin reuptake inhibitors in patients with depression Valid to November 2022 bpac nz better medicin e Audit Focus This audit helps health professionals
Chronic Pain Care Management in Primary Care 12/16/2010. Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences
CARE MANAGEMENT FOR CHRONIC PAIN Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences Dec 16, 2010 Agenda Physical and Emotional Pain Collaborative Care and Care Management for Pain Treatments
HYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
Juvenile Depression.
Juvenile Depression Karen Dineen Wagner, MD, PhD Titus Harris Chair Professor and Chair Department of Psychiatry & Behavioral Sciences University of Texas Medical Branch Galveston, Texas Disclosure (Past
Department of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
There are different types of depression. This information is about major depression. It's also called clinical depression.
Patient information from the BMJ Group Depression in adults Depression is not the same as feeling a bit low. Depression is an illness that can affect how you feel and behave for weeks or months at a time.
Pedersen et al. Implementation Science (2018) 13:99 https://doi.org/ /s (Continued on next page)
Pedersen et al. Implementation Science (2018) 13:99 https://doi.org/10.1186/s13012-018-0788-8 SYSTEMATIC REVIEW Open Access Elusive search for effective provider interventions: a systematic review of provider